Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2015-004425-13-SE
EUCTR2015-004425-13-SE
Active, not recruiting
Not Applicable

Prospective evaluation of 68-Ga-PSMA-PET and early PSA kinetics during salvage radiotherapy for personalizing the management of men with relapse of prostate cancer after radical prostatectomy. - PROPER

Skåne University Hospital, Department of Oncology0 sites100 target enrollmentDecember 10, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Skåne University Hospital, Department of Oncology
Enrollment
100
Status
Active, not recruiting
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 10, 2015
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Sponsor
Skåne University Hospital, Department of Oncology

Eligibility Criteria

Inclusion Criteria

  • •\- Confirmed prostate cancer
  • •\- PSA recurrence after prostatectomy (defined as a PSA ? 0\.2 ng/ml confirmed in a second sample)
  • •\- Expected Life\-expectancy of ? 10 years
  • •\- Any pT, pN0/X, M0/X
  • •\- Patients suitable for radiotherapy
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 40
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •\- Previous malignancy other than basalioma within the last 5 years
  • •\- Previous or ongoing hormonal therapy
  • •\- Inability to sign written informed concent

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Evaluation of 68Ga-PSMA PET-CT in the initial extension assessment of advanced renal cell carcinomaa prospective, multicenter, open studyrenal cell cancer (RCC)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-003760-47-FRAssistance Publique Hôpitaux de Marseille44
Active, not recruiting
Phase 1
Evaluation of [68Ga]PSMA PET/MRI in intermediate and high risk prostate cancer – a comparison with mpMRI, [11C]ACE PET/CT and histopathological validatio
EUCTR2015-005046-55-SEmeå University Hospital
Active, not recruiting
Phase 1
Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2016-000842-79-BEInstitut Jules Bordet75
Recruiting
Not Applicable
PSMA-PET/CT in Primary Staging of Prostate Cancer
NL-OMON28484niversity Medical Center Utrecht100
Completed
Not Applicable
68Ga-FAPI-46 and 18F-FDG PET/CT for evaluation of head and neck squamous cell carcinoma: a comparative analysisDetection of primary cancer and metastatic lesions in patients with HNSCC.Head and Neck Neoplasms68Ga-FAPI
TCTR20210902003ational Cyclotron and PET Centre, Chulabhorn Hospital40